Document is current
Any future updates will be listed below
-
Authors
Perez-Penco, Maria
Byrdal, Mikkel
Lara de la Torre, Lucia https://orcid.org/0000-0002-9789-6469
Ballester, Marta
Khan, Shawez https://orcid.org/0000-0003-1682-4824
Siersbæk, Majken
Lecoq, Inés https://orcid.org/0000-0001-6121-2750
Madsen, Cecilie Oelvang
Kjeldsen, Julie Westerlin
Svane, Inge Marie https://orcid.org/0000-0002-9451-6037
Hansen, Morten
Donia, Marco https://orcid.org/0000-0003-4966-9752
Johansen, Julia Sidenius
Olsen, Lars Rønn
Grøntved, Lars
Chen, Inna Markovna
Arnes, Luis
Holmström, Morten Orebo
Andersen, Mads Hald https://orcid.org/0000-0002-2914-9605
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 10 November 2024
First Online: 9 December 2024
Competing interests
: IL is an employee at IO Biotech. IMS has received research funding from Evaxion Biotech, Adaptimmune, IO Biotech, Lytix Biopharma, TILT Biotherapeutics, Enara Bio, and Asgard Biotech. IMS has received consulting fees for MSD, IO Biotech, Novartis, Pierre Fabre, and TILT Biotherapeutics. The IMS has received travel support from the MSD. IMS has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from MSD, Novartis, Sanofi Aventis, Pierre Fabre, BMS, Novo Nordisk, and Takeda. MD is an advisor of Achilles Therapeutics and has received access to proprietary data from Bristol Myers Squibb and Genentech. IMC has received research funding from Roche, Bristol Myers Squibb, Celgene, Genis, and Varian Medical Systems, AstraZeneca, and Genmab. Travel and accommodation expenses for IMC have been covered by Roche, Bristol Myers Squibb, Celgene, Bayer, and AstraZeneca. The IMC has an advisory role at Amgen, AstraZeneca, and ANOCCA. MHA has developed an invention based on the use of transforming growth factor-β–derived peptides for vaccinations. A patent application directed to the invention is owned by the company IO Biotech ApS and lists the MHA as the sole inventor. MHA is an advisor and shareholder at IO Biotech. The additional authors declare that they have no competing interests.
